Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes
- 1 May 2003
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 101 (9) , 3674-3680
- https://doi.org/10.1182/blood-2002-07-2339
Abstract
Acadesine, 5-aminoimidazole-4-carboxamide (AICA) riboside, induced apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells in all samples tested (n = 70). The half-maximal effective concentration (EC50) for B-CLL cells was 380 ± 60 μM (n = 5). The caspase inhibitor Z-VAD.fmk completely blocked acadesine-induced apoptosis, which involved the activation of caspase-3, -8, and -9 and cytochrome c release. Incubation of B-CLL cells with acadesine induced the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), indicating that it is activated by acadesine. Nitrobenzylthioinosine (NBTI), a nucleoside transport inhibitor, 5-iodotubercidin, an inhibitor of adenosine kinase, and adenosine completely inhibited acadesine-induced apoptosis and AMPK phosphorylation, demonstrating that incorporation of acadesine into the cell and its subsequent phosphorylation to AICA ribotide (ZMP) are necessary to induce apoptosis. Inhibitors of protein kinase A and mitogen-activated protein kinases did not protect from acadesine-induced apoptosis in B-CLL cells. Moreover, acadesine had no effect on p53 levels or phosphorylation, suggesting a p53-independent mechanism in apoptosis triggering. Normal B lymphocytes were as sensitive as B-CLL cells to acadesine-induced apoptosis. However, T cells from patients with B-CLL were only slightly affected by acadesine at doses up to 4 mM. AMPK phosphorylation did not occur in T cells treated with acadesine. Intracellular levels of ZMP were higher in B-CLL cells than in T cells when both were treated with 0.5 mM acadesine, suggesting that ZMP accumulation is necessary to activate AMPK and induce apoptosis. These results suggest a new pathway involving AMPK in the control of apoptosis in B-CLL cells and raise the possibility of using acadesine in B-CLL treatment.Keywords
This publication has 49 references indexed in Scilit:
- Inhibition of Nucleoside Transport by p38 MAPK InhibitorsPublished by Elsevier ,2002
- Cell Cycle Regulation via p53 Phosphorylation by a 5′-AMP Activated Protein Kinase Activator, 5-Aminoimidazole- 4-Carboxamide-1-β- -Ribofuranoside, in a Human Hepatocellular Carcinoma Cell LineBiochemical and Biophysical Research Communications, 2001
- Cytosolic 5′-nucleotidase hyperactivity in erythrocytes of Lesch–Nyhan syndrome patientsNeuroReport, 2000
- Regulation of Nucleoside Transport by Lipopolysaccharide, Phorbol Esters, and Tumor Necrosis Factor-α in Human B-lymphocytesPublished by Elsevier ,1998
- Chronic lymphocytic leukemiaCurrent Opinion in Hematology, 1998
- Characterization of the AMP-activated Protein Kinase Kinase from Rat Liver and Identification of Threonine 172 as the Major Site at Which It Phosphorylates AMP-activated Protein KinaseJournal of Biological Chemistry, 1996
- Nucleoside transporters, bcl‐2 and apoptosis in CLL cells exposed to nucleoside analogues in vitroEuropean Journal of Haematology, 1996
- AICA‐Riboside: Safety, Tolerance, and Pharmacokinetics of a Novel Adenosine‐Regulating AgentThe Journal of Clinical Pharmacology, 1991
- Disruption of the purine nucleotide cycle by inhibition of adenylosuccinate lyase produces skeletal muscle dysfunction.Journal of Clinical Investigation, 1984
- Aminoimidazole carboxamide ribonucleoside toxicity: A model for study of pyrimidine starvationJournal of Cellular Physiology, 1981